384 related articles for article (PubMed ID: 28545997)
1. Factors Associated With Survival Following Radium-223 Treatment for Metastatic Castration-resistant Prostate Cancer.
Wong WW; Anderson EM; Mohammadi H; Daniels TB; Schild SE; Keole SR; Choo CR; Tzou KS; Bryce AH; Ho TH; Quevedo FJ; Vora SA
Clin Genitourin Cancer; 2017 Dec; 15(6):e969-e975. PubMed ID: 28545997
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration-resistant prostate cancer treated with Radium-223.
Al-Ezzi EM; Alqaisi HA; Iafolla MAJ; Wang L; Sridhar SS; Sacher AG; Fallah-Rad N; Jiang DM; Watson GA; Catton CN; Warde PR; Hamilton RJ; Fleshner NE; Zlotta AR; Hansen AR
Cancer Med; 2021 Sep; 10(17):5775-5782. PubMed ID: 34254464
[TBL] [Abstract][Full Text] [Related]
3. Clinical indicators for predicting prognosis after radium-223 administration in castration-resistant prostate cancer with bone metastases.
Yamamoto Y; Okuda Y; Kanaki T; Tanaka R; Nagahara A; Nakai Y; Nakayama M; Kakimoto KI; Nishimura K
Int J Clin Oncol; 2021 Jan; 26(1):192-198. PubMed ID: 32875513
[TBL] [Abstract][Full Text] [Related]
4. Real-world Outcomes and Factors Predicting Survival and Completion of Radium 223 in Metastatic Castrate-resistant Prostate Cancer.
Parikh S; Murray L; Kenning L; Bottomley D; Din O; Dixit S; Ferguson C; Handforth C; Joseph L; Mokhtar D; White L; Wright G; Henry AM
Clin Oncol (R Coll Radiol); 2018 Sep; 30(9):548-555. PubMed ID: 29934104
[TBL] [Abstract][Full Text] [Related]
5. Complete Cycles of Radium-223 Improve Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer: A Retrospective Study.
Yang HC; Chang LW; Li JR; Wang SS; Yang CK; Chen CS; Lu K; Chen CC; Wang SC; Lin CY; Cheng CL; Ou YC; Chiu KY; Hung SC
Anticancer Res; 2023 Apr; 43(4):1809-1816. PubMed ID: 36974814
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects.
Isaacsson Velho P; Qazi F; Hassan S; Carducci MA; Denmeade SR; Markowski MC; Thorek DL; DeWeese TL; Song DY; Tran PT; Eisenberger MA; Antonarakis ES
Eur Urol; 2019 Aug; 76(2):170-176. PubMed ID: 30293905
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer.
Matsubara N; Nagamori S; Wakumoto Y; Uemura H; Kimura G; Yokomizo A; Kikukawa H; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Tsutsui H; Uemura H
Int J Clin Oncol; 2018 Feb; 23(1):173-180. PubMed ID: 28770408
[TBL] [Abstract][Full Text] [Related]
8. The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.
Liu AJ; Kosiorek HE; Ueberroth BE; Jaeger E; Ledet E; Kendi AT; Tzou K; Quevedo F; Choo R; Moore CN; Ho TH; Singh P; Keole SR; Wong WW; Sartor O; Bryce AH
Prostate; 2022 Sep; 82(12):1202-1209. PubMed ID: 35652618
[TBL] [Abstract][Full Text] [Related]
9. A 3-variable prognostic score (3-PS) for overall survival prediction in metastatic castration-resistant prostate cancer treated with
Frantellizzi V; Farcomeni A; Follacchio GA; Pacilio M; Pellegrini R; Pani R; De Vincentis G
Ann Nucl Med; 2018 Feb; 32(2):142-148. PubMed ID: 29285670
[TBL] [Abstract][Full Text] [Related]
10. Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study.
Romero-Laorden N; Lorente D; de Velasco G; Lozano R; Herrera B; Puente J; López PP; Medina A; Almagro E; Gonzalez-Billalabeitia E; Villla-Guzman JC; González-Del-Alba A; Borrega P; Laínez N; Fernández-Freire A; Hernández A; Rodriguez-Vida A; Chirivella I; Fernandez-Parra E; López-Campos F; Isabel Pacheco M; Morales-Barrera R; Fernández O; Villatoro R; Luque R; Hernando S; Castellano DC; Castro E; Olmos D
Eur Urol Oncol; 2024 Jun; 7(3):447-455. PubMed ID: 37838555
[TBL] [Abstract][Full Text] [Related]
11. Assessing Radiographic Response to
Anand A; Trägårdh E; Edenbrandt L; Beckman L; Svensson JH; Thellenberg C; Widmark A; Kindblom J; Ullén A; Bjartell A
J Nucl Med; 2020 May; 61(5):671-675. PubMed ID: 31586004
[TBL] [Abstract][Full Text] [Related]
12. Review of Palliative
Arays R; Ahmad Z; Howard L; Veselicky K; Kolodney J; SijinWen ; Hogan T
J Nucl Med Technol; 2021 Mar; 49(1):70-74. PubMed ID: 33219158
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen flare induced by
Castello A; Macapinlac HA; Lopci E; Santos EB
Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2256-2263. PubMed ID: 29785515
[TBL] [Abstract][Full Text] [Related]
14. 223Ra Therapy in Patients With Advanced Castration-Resistant Prostate Cancer With Bone Metastases: Lessons from Daily Practice.
van der Doelen MJ; Kuppen MCP; Jonker MA; Mehra N; Janssen MJR; van Oort IM; Gerritsen WR
Clin Nucl Med; 2018 Jan; 43(1):9-16. PubMed ID: 29166331
[TBL] [Abstract][Full Text] [Related]
15. Novel nomogram developed for determining suitability of metastatic castration-resistant prostate cancer patients to receive maximum benefit from radium-223 dichloride treatment-Japanese Ra-223 Therapy in Prostate Cancer using Bone Scan Index (J-RAP-BSI) Trial.
Kitajima K; Igeta M; Kuyama J; Kawahara T; Suga T; Otani T; Sugawara S; Kono Y; Tamaki Y; Seko-Nitta A; Ishiwata Y; Ito K; Toriihara A; Watanabe S; Hosono M; Miyake H; Yamamoto S; Narita M; Daimon T; Yamakado K
Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1487-1498. PubMed ID: 36539508
[TBL] [Abstract][Full Text] [Related]
16. Impact of pre-treatment variables on the completion of
Lavelli V; Nappi AG; Caputo P; Asabella AN; Fanelli M; Sardaro A; Altini C; Ferrari C; Rubini G
Hell J Nucl Med; 2019; 22 Suppl 2():153-163. PubMed ID: 31802056
[TBL] [Abstract][Full Text] [Related]
17. Radium-223 dichloride treatment in metastatic castration-resistant prostate cancer in Finland: A real-world evidence multicenter study.
Hyväkkä A; Kääriäinen OS; Utriainen T; Löyttyniemi E; Mattila K; Reinikainen P; Sormunen J; Jääskeläinen M; Auvinen P; Minn H; Sundvall M
Cancer Med; 2023 Feb; 12(4):4064-4076. PubMed ID: 36156455
[TBL] [Abstract][Full Text] [Related]
18. Radium-223 for primary bone metastases in patients with hormone-sensitive prostate cancer after radical prostatectomy.
Wenter V; Herlemann A; Fendler WP; Ilhan H; Tirichter N; Bartenstein P; Stief CG; la Fougère C; Albert NL; Rominger A; Gratzke C
Oncotarget; 2017 Jul; 8(27):44131-44140. PubMed ID: 28484088
[TBL] [Abstract][Full Text] [Related]
19. Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.
Heidenreich A; Gillessen S; Heinrich D; Keizman D; O'Sullivan JM; Carles J; Wirth M; Miller K; Reeves J; Seger M; Nilsson S; Saad F
BMC Cancer; 2019 Jan; 19(1):12. PubMed ID: 30612558
[TBL] [Abstract][Full Text] [Related]
20. The Clinical Efficacy of Radium-223 for Bone Metastasis in Patients with Castration-Resistant Prostate Cancer: An Italian Clinical Experience.
De Luca R; Costa RP; Tripoli V; Murabito A; Cicero G
Oncology; 2018; 94(3):161-166. PubMed ID: 29241166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]